Dermata Therapeutics (DRMA) vs Traws Pharma (TRAW)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Traws Pharma is the larger company by market cap ($2.7 million vs $2.5 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DRMA | TRAW |
|---|---|---|
| Share price | $0.5095 | $0.175 |
| Market cap | $2.51M | $2.69M |
| 1-day change | -4.23% | -23.91% |
| EPS (TTM) | $-3.28 | $-1.71 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $2.79M |
| Revenue growth (YoY) | — | +1134.51% |
| Net income (latest FY) | $-7.56M | $9.17M |
| Operating margin | — | -640.68% |
| Net margin | — | 328.67% |
| 52-week high | $4.66 | $3.23 |
| 52-week low | $0.50 | $0.1698 |
| Distance from 52-week high | -89.07% | -94.58% |
| Analyst consensus | none | none |
| Avg. price target upside | +685.08% | +471.43% |
| Average volume | 2.78M | 610.04K |
| Shares outstanding | 4.93M | 15.37M |
| Employees | 9 | 4 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Dermata Therapeutics
DRMA stock →Dermata Therapeutics, Inc. engages in the development and distribution of over-the-counter pharmaceutical dermatology-focused products in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations · 9 employees
About Traws Pharma
TRAW stock →Traws Pharma, Inc., a clinical-stage biopharmaceutical company, develops small synthetic molecules for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID-19 that are designed to address treatment resistance, such as TRX01 (Ratutrelvir), an inhibitor in development for the treatment of COVID-19; and Tivoxavir marboxil, an endonuclease inhibitor in development for the treatment of bird flu and seasonal influenza.
Health Care · Biotechnology: Pharmaceutical Preparations · 4 employees
DRMA vs TRAW FAQ
Which is bigger, Dermata Therapeutics or Traws Pharma?
Traws Pharma (TRAW) is larger, with a market capitalization of $2.69M compared with $2.51M for Dermata Therapeutics (DRMA).
Are Dermata Therapeutics and Traws Pharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.